TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06501963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine
Description: The FDA-approved live attenuated seasonal influenza vaccine (LAIV) (FluMist®, AstraZeneca) is licensed in the US for people 2-49 years of age. The approved seasonal LAIV at the time of study enrollment will be obtained from the manufacturer. LAIV will be administered by a study nurse or health care provider at the Hope Clinic as a single 0.2 milliliter (mL) dose given as 0.1 mL spray in each nostril.
Study: NCT05690646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Description: nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Description: nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: ursodeoxycholic acid 15mg/kg/day bid for5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: ursodeoxycholic acid 15mg/kg/day bid for5 days
Study: NCT04204616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Nemolizumab 30 mg will be administered as subcutaneous (SC) injection.
Study: NCT06399107

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Drug Product is administered by IV infusion following myeloablative conditioning with busulfan
Description: An autologous CD34+ cell-enriched population from patients with sickle cell disease (SCD), which includes hematopoietic stem cells (HSCs) that have been transduced with the BAH243 lentiviral vector (LVV) carrying the βA-T87Q-globin gene, is preserved in a cryopreservation solution.
Study: NCT04758988

Intervention type: OTHER
Group type: OTHER
Intervention: DermLoop Learn
Description: DermLoop Learn is our AI augmented digital online educational system with case training on a library of 10,000+ benign and malignant skin lesion as well as written learning modules for the most common skin lesion diagnosis.
Study: NCT06487936

Intervention type: DEVICE
Intervention: TransLoc 3D SI Joint Fusion System
Description: Satisfaction survey will be administered to collect real world evidence on patients that previously received the TransLoc 3D System commercially.
Study: NCT05648539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The mini apps named SOUL GYM on the Wechat
Description: Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The mini apps named SOUL GYM on the Wechat
Description: Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
Study: NCT04779034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of heart rate variability
Description: Heart rate variation will be evaluated with the Polar RS800CX model heart rate monitor
Study: NCT05277532

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training (HIIT)
Description: HIIT performed either in the morning or in the afternoon

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training (HIIT)
Description: HIIT performed either in the morning or in the afternoon
Study: NCT05544760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CatchU Intervention
Description: The CatchU Intervention arm will receive individualized recommendations (adapted from the CDC STEADI program) as outlined on the CatchU physician report sent to the participants physicians. These recommendations in combination with falls intervention referrals and falls counseling tips will be monitored and statistical investigation of the impact of CatchU intervention in preventing future falls will be determined.
Study: NCT05498870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block (ACB) Only
Description: Patients will receive an ACB with lidocaine skin wheal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block (ACB) + iPACK Block
Description: Patients will receive an ACB with iPACK block
Study: NCT06121921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative multi-component intervention
Description: Physical Component~Self-directed daily non-ambulatory exercise programme, comprising:~* Rubber ball squeezes (3 sets of 12 reps, per hand)~* Bicep curls (3 sets of 12 reps)~* Leg extensions (3 sets of 12 reps)~* Chair rises (3 sets of 12 reps)~* Arm stretches (3 sets of 3 reps) Additional encouragement to mobilise~Cognitive Component:~Delirium prevention strategies including orientation, hydration, bowel/bladder function, infection control, analgesia, polypharmacy and cognitive stimulation~Nutritional Component:~* Formal dietician review if MUST score ≥ 2~* IV ferritin if LVEF \<45% and serum ferritin \<100ng/mL or ferritin 100-299ng/mL with TSAT \<20%
Study: NCT05662722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: percutaneous needle electrolysis
Description: It´s an intervention of physiotherapy. It´s an invasive technique.

Intervention type: OTHER
Group type: OTHER
Intervention: Dry needling
Description: It´s an intervention of physiotherapy. It´s an invasive technique.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham needling
Description: It´s an intervention of physiotherapy. It´s an invasive technique simulation.
Study: NCT06451458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECHO program for DMMC
Description: For the intervention, an 18-month ECHO program of weekly videoconference sessions will mentor healthcare teams on complex care strategies for patients with DMMC, emphasizing evidence-based best practices related to common chronic conditions (e.g., diabetes, CKD, hypertension, hyperlipidemia and depression). Mentorship will be provided by a multidisciplinary team of experts including a patient representative, diabetes educator, endocrinologist, psychiatrist, a nephrologist/kidney disease and hypertension specialist, a clinical pharmacist, and a cardiology consultant. Each session will consist of a didactic presentation, de-identified patient case presentations, and questions and discussion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The comparator will consist of 10 PMS FQHC clinics with healthcare teams practicing usual care according to PMS standard practices during the 18 months of the intervention arm.
Study: NCT06497985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5mg/kg intravenously (IV) Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fruquintinib
Description: 5mg orally QD
Study: NCT05860751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry Needling with electrical stimulation
Description: Administered for a total of 2 sessions at a frequency of once per week. The target muscles to be needled will include the gastronemius, soleus, vastus lateralis, rectus femoris, anterior tibialis, posterior tibialis, biceps femoris, and gluteus medius.
Study: NCT05479981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOC 1001
Description: AOC 1001 will be administered by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOC 1001
Description: AOC 1001 will be administered by intravenous (IV) infusion.
Study: NCT04966169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GentleWave System
Description: The GentleWave hydrodynamic cavitation system is a 510k FDA-approved multisonic energy system that is used in complex root canal procedures.
Study: NCT04650256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM)
Description: CAM will be applied topically on the chest wall once during the day (or immediately after radiotherapy) and once at night daily.
Study: NCT06641050

Intervention type: DIAGNOSTIC_TEST
Intervention: Triage+ Score
Description: The TriAGE+ score is used to evaluate the risk of cerebrovascular disease in patients presenting with dizziness. The score assists in determining the necessity of advanced diagnostic evaluation for stroke, potentially improving diagnostic accuracy and patient outcomes.
Study: NCT06639581

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 20 per minute stimulus
Description: crossover randomized mechanical dorsal stimuli -for one minute each- at 20-rates per minute

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 20 per minute stimulus
Description: crossover randomized mechanical dorsal stimuli -for one minute each- at 20-rates per minute

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 20 per minute stimulus
Description: crossover randomized mechanical dorsal stimuli -for one minute each- at 20-rates per minute

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 30 per minute stimulus
Description: crossover randomized mechanical dorsal stimuli -for one minute each- at 30 rates per minute

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 30 per minute stimulus
Description: crossover randomized mechanical dorsal stimuli -for one minute each- at 30 rates per minute

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 30 per minute stimulus
Description: crossover randomized mechanical dorsal stimuli -for one minute each- at 30 rates per minute

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 40 per minute stimulus
Description: crossover randomized mechanical dorsal stimuli -for one minute each- at 40 rates per minute

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 40 per minute stimulus
Description: crossover randomized mechanical dorsal stimuli -for one minute each- at 40 rates per minute

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 40 per minute stimulus
Description: crossover randomized mechanical dorsal stimuli -for one minute each- at 40 rates per minute
Study: NCT06640946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical lidocaine
Description: Topical lidocaine cream prior to laser follicle ablation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham cream
Description: Placebo cream without lidocaine will be placed and removed before laser.
Study: NCT05155085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1)monoclonal antibody directed against Siglec-8

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study: NCT06641726

Intervention type: OTHER
Intervention: Not applicable- observational study
Description: This is non-interventional, cross-sectional observational study and thus there is no intervention.

Intervention type: OTHER
Intervention: Not applicable- observational study
Description: This is non-interventional, cross-sectional observational study and thus there is no intervention.

Intervention type: OTHER
Intervention: Not applicable- observational study
Description: This is non-interventional, cross-sectional observational study and thus there is no intervention.
Study: NCT06640348

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06641206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 1 ml of triamcinolone acetonide was used to prepare a solution for knee injection for patients with Chronic Knee Pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 20mg of bupivacaine hydrochloride was used to prepare a solution for knee injection for patients with Chronic Knee Pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine solution was prepared by mixing Dexmedetomidine in a dose of 3 µg/kg in 5-ml saline
Study: NCT04801173

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Very low calorie ketogenic diet
Description: Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie standard diet
Description: Low calorie standard diet with no specified dietary supplement addition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low calorie standard diet
Description: Low calorie standard diet with no specified dietary supplement addition
Study: NCT04260854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Bupivacaine hydrochloride (Hospira, Inc) is an FDA approved, local, injectable indicated for the production of local or regional anesthesia or analgesia for surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline injections.
Study: NCT06643078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL231 Solution for Inhalation
Description: HL231 Solution for Inhalation, 3ml:261 μg/141μg, once per day via PARI BOY nebulizer, consisting of a fixed dose combination of indacaterol 261µg and glycopyrronium 141µg, treatment period; 52-weeks fixed dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultibro 110μg/50 μg
Description: Ultibro capsule for inhalation once per day via Breezhaler, consisting of a fixed dose combination of indacaterol 110µg and glycopyrronium 50µg, treatment period; 52-weeks fixed dose.
Study: NCT06639945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial MR-guided focused ultrasound
Description: MRI-guided transcranial focused ultrasound (MRgFUS) combines magnetic resonance imaging (MRI) with focused ultrasound to target specific areas in the brain non-invasively. MRgFUS allows for treatment without surgical incisions, leading to fewer risks and a quicker recovery. MRI provides real-time imaging that helps precisely locate and treat affected brain regions, such as the thalamus or globus pallidus.The procedure allows for continuous monitoring of the treatment effects, enabling adjustments as needed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial MR-guided focused ultrasound
Description: MRI-guided transcranial focused ultrasound (MRgFUS) combines magnetic resonance imaging (MRI) with focused ultrasound to target specific areas in the brain non-invasively. MRgFUS allows for treatment without surgical incisions, leading to fewer risks and a quicker recovery. MRI provides real-time imaging that helps precisely locate and treat affected brain regions, such as the thalamus or globus pallidus.The procedure allows for continuous monitoring of the treatment effects, enabling adjustments as needed.
Study: NCT06637111

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided office hysteroscopy group
Description: One hour before office hysteroscopy, 100 mg of diclofenac potassium will be administered per orem. The patients will be asked to drink about one liter of water and to avoid urination before the procedure Moreover, a few minutes prior to the office hysteroscopy, 3 ml of 5% lidocaine and prilocaine topical cream will be introduced into the endocervical canal.~All procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.~A 5 Fr grasper and 5 Fr scissors will be used to widen the stenotic internal or external ostia.~Transabdominal ultrasound will be used to guide the access of the hysteroscope to the uterine cavity
Study: NCT06047925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D printed crown
Description: Reduction will be performed on the occlusal surface using a flame stone or a wheel stone, to perform occlusal clearance by 1 mm. Reduction will be performed by 1 mm on the mesial, distal, buccal and lingual surfaces of the tooth. Impression for the preparation will be taken using putty and light poly vinyl siloxane material. Temporary crown will be placed above the preparation as temporisation.The impression will be sent to the lab .The preparation will be optically scanned in the lab and the restoration will be digitally designed using computer designing software.The crown will be printed using 3D printer using hybrid resin(micro-filled hybrid material) material.The 3d printed crown is cemented with resin cement.
Study: NCT06637111

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional office hysteroscopy group
Description: One hour before office hysteroscopy, 100 mg of diclofenac potassium will be administered per orem . The patients will be asked to drink about one liter of water and to avoid urination before the procedure Moreover, a few minutes prior to the office hysteroscopy, 3 ml of 5% lidocaine and prilocaine topical cream will be introduced into the endocervical canal.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.~A 5 Fr grasper and 5 Fr scissors will be used to widen the stenotic internal or external ostia.
Study: NCT06047925

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stanless steel crown
Description: The occlusal surface of the tooth should be reduced by about 1.5 mm, maintaining its occlusal contour or until the tooth is out of occlusion with adequate room to fit a crown.Proximally, tooth reduction will be made through the mesial and distal contact areas, then roundation of line angles to avoid the creation of ledges or steps.The crown selection will be done by trial and error or by measuring the mesiodistal dimension of the tooth space with dividers. It can also be helpful to measure the dimension of the contralateral tooth. A correctly fitting crown should snap or click at try in.
Study: NCT06645392

Intervention type: DEVICE
Intervention: visual transparent bladed trocar of
Description: visual transparent bladed trocar of diameter 10 mm and Ternamian bladeless trocar of diameter 10 mm

Intervention type: DEVICE
Intervention: Ternamian bladeless trocar
Description: Ternamian bladeless trocar of diameter 10 mm
Study: NCT05227378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: neoantigen tumor vaccine with or without PD-1/L1
Description: personalized neoantigen tumor vaccine with or without PD-1/L1
Study: NCT06643624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vision Training Program
Description: Vision training (experimental) group; vision training program was applied in addition to routine training programs. For 8 weeks, 5 sessions per week for a total of 40 sessions of vision training were applied by a physiotherapist. In the first 2 weeks, each movement was applied for 1 minute for a total of 10 minutes. In the 3rd week, each movement was practiced for 1.5 minutes for a total of 15 minutes. In weeks 4-8, each movement was performed for 2 minutes each for a total of 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Training Program
Description: All athletes performed their routine training for wrestling 6 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Training Program
Description: All athletes performed their routine training for wrestling 6 days a week.
Study: NCT05927298

Intervention type: OTHER
Intervention: Non-interventional
Description: Standard of care intervention

Intervention type: OTHER
Intervention: Non-interventional
Description: Standard of care intervention
Study: NCT04137757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Body Negative Pressure
Description: Lower body negative pressure will be applied.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Pressure
Description: Noise will be turned on but no pressure will be applied.
Study: NCT05743673

Intervention type: DEVICE
Intervention: Shape II
Description: cardiopulmonary exercise testing apparatus
Study: NCT05406401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab Vedotin
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab Vedotin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab Biosimilar
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab Biosimilar
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: IV or oral administration (per local guidelines)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: IV or oral administration (per local guidelines)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: IV or oral administration (per local guidelines)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: IV or oral administration (per local guidelines)
Study: NCT06505395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2008 injection
Description: The patients will accept SYHX2008 injection by subcutaneous administration every cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandostatin LAR@
Description: The patients will accept Sandostatin LAR@ by intra-muscular administration every cycle.
Study: NCT04806399

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Materials and Decision Counseling
Description: Participants in the active comparator arm will receive an introductory letter and lung cancer screening educational materials. A site care coordinator will contact each participant post receiving materials.